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Background: Mannan-binding lectin (MBL) is a pattern-recognition molecule present in serum, which is involved
in the innate immune defense by activating complement and promoting opsonophagocytosis. Dendritic cells (DCs)
are professional antigen presenting cells (APCs) that are crucial for the initiation of adaptive immunity.
Lipopolysaccharide (LPS) has been shown to be a strong activator of the inflammatory response and immune
regulation. We first examined whether MBL modulated LPS-induced cellular responses, then investigated possible
mechanisms of its inhibitory effect.
Results: MBL at higher concentrations (10-20 μg/ml) significantly attenuated LPS-induced maturation of monocyte-
derived DCs (MDCs) and production of proinflammatory cytokines (e.g., IL-12 and TNF-a), and inhibited their ability
to activate allogeneic T lymphocytes. It bound to immature MDCs at physiological calcium concentrations, and was
optimal at supraphysiological calcium concentrations. MBL also bound directly to immature MDCs and attenuated
the binding of LPS to the cell surfaces, resulting in decreased LPS-induced nuclear factor-B (NF-B) activity in
these cells.
Conclusion: All these data suggest that MBL could affect the functions of DCs by modifying LPS-induced cellular
responses. This study supports an important role for MBL in the regulation of adaptive immune responses and
inflammatory responses.
Background
Mannan-binding lectin (MBL), a member of the collec-
tin family in the C-type lectin superfamily, is a multi-
meric protein containing collagen-like sequences. It is
synthesized and secreted into the blood by hepatocytes.
It has the overall ‘bundle-of-tulips’ structure first
described for C1q [1]. The MBL polypeptide comprises
four domains: a cysteine-rich N-terminal domain, a col-
lagen-like region (CLR) that contains Gly-X-Y repeats
(where X is any amino acid and Y is often hydroxypro-
line or hydroxylysine), a neck region and a C-terminal
carbohydrate-recognition domain (CRD) [2-7]. The
MBL polymer is composed of as many as six homoge-
nous subunits [8], but only the more highly polymeric
forms have biological activity and can fix complement.
Dendritic cells (DCs) are highly efficient antigen-pre-
senting cells that play a central role in orchestrating
adaptive immune responses to pathogens [9]. In their
immature form (imDCs), they can capture antigen very
efficiently by macropinocytosis, endocytosis [10], and
phagocytosis [11] through different cell surface mole-
cules, e.g. mannose receptor, Toll-like receptors (TLRs)
or scavenger receptors. To elicit an immune response,
DCs must undergo a maturation process, which is
initiated by inflammatory signals and is completed after
contact with T cells. Maturation enables DCs to migrate
from peripheral tissues to lymphoid organs and to
acquire a very potent antigen-presenting capacity.
Mature DCs are also the initial and most prominent
source of the cytokines that govern the development of
Th1 responses (e.g., IL-12). DC maturation is known to
be induced by several stimuli, including bacterial com-
ponents [e.g., lipopolysaccharide (LPS)], heat shock
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factors such as inflammatory cytokines [12].
It has been reported that other members of the solu-
ble defensive collagen family such as surfactant protein
A (SP-A), surfactant protein D (SP-D) and complement
C1q, have roles in immune regulation by interacting
with various cells. For instance, SP-A inhibits the differ-
entiation and maturation of DCs [13] and modulates
cellular responses induced by LPS through interacting
with CD14 [14]; SP-A suppresses TNF-a secretion from
alveolar macrophages stimulated by LPS [15], and SP-A-
deficient mice produce significantly more TNF-a than
wild-type mice after intratracheal LPS administration
[16]. SP-D enhances bacterial antigen presentation by
bone marrow-derived DCs [17]. C1q regulates LPS-
induced cytokine production in bone marrow-derived
DCs [18] and induces maturation of human DCs [19].
As a key soluble pattern recognition molecule in the
innate immune system, MBL has been reported to influ-
ence the cytokine network after stimulation by various
microorganisms [20-23]. To date, however, little knowl-
edge has been obtained about its role in the regulation
of adaptive response. Since DCs play key roles in initiat-
ing adaptive responses, it will be useful to know whether
and how this member of the collectin family regulates




MBL was purified from pooled human plasma samples
containing high concentrations (approximately 2500 μg
MBL/L on average). SDS-PAGE and western blotting
showed that the highly purified MBL was a functional
multimer composed of 32KD peptide chains (Figure 1).
It was highly bioactive, as demonstrated by a ligand-
binding assay and yeast coagulation (data not shown).
MBL suppresses LPS-induced MDC maturation
It is well known that DC maturation is induced by LPS.
During DC maturation, the expression of receptors
required for phagocytosis is down-regulated, whereas
MHCII and co-stimulatory molecules such as CD80 and
CD86 are up-regulated [24]. To investigate whether
MBL influences DC maturation, imMDCs were stimu-
lated with smooth LPS (100 ng/ml) in the presence of
increasing concentrations of MBL (0, 1, 10, 20 μg/ml)
for 2 days. Cell maturation was assessed by flow cyto-
metry (FCM). As shown in Figure 2, LPS induced ele-
vated expression of CD83, CD86, and MHC II, but
these effects were strongly inhibited by MBL at higher
concentrations (10-20 μg/ml) compared with the corre-
sponding cells without MBL treatment (P < 0.05); HSA
(20 μg/ml) and lower MBL concentrations (1 μg/ml)
had no such effect. Inclusion of anti-MBL polyclonal
antibody (pAb) during the preincubation of the cells
with MBL restored the expression of CD83, CD86, and
MHC II on DCs (Figure 2), indicating that MBL specifi-
cally inhibited the interaction between LPS and
imMDCs.
MBL inhibits TNF-a and IL-12 p40+p70 production from
LPS-stimulated MDCs
ImMDCs were stimulated with LPS and exhibited maxi-
mal response to secreted proinflammatory cytokines
such as IL-12 and TNF-a (data not shown). Cytokines
produced by MDCs are known to be important in regu-
lating the adaptive immune response, directing it to
either the Th1 or the Th2 pathway. To investigate
whether MBL affects cytokine production by MDCs sti-
mulated with LPS, imMDCs were stimulated with LPS
(100 ng/ml) in the presence of increasing concentrations
of MBL (0, 1, 10, 20 μg/ml) for 24 h, and the superna-
tants were analyzed by ELISA. As shown in Figure 3,
the inductions of TNF-a and IL-12 p40+p70 by LPS
were strongly inhibited by MBL at higher concentrations
(10-20 μg/ml), compared with the corresponding
imMDCs without MBL treatment (P < 0.05), but HSA
(20 μg/ml) and lower MBL concentrations (1 μg/ml)
had no such effect. Inclusion of Anti-MBL pAb during
the preincubation of the cells with MBL restored the
secretion of TNF-a and IL-12 p40+p70 (Figure 3), indi-
cating that the inhibitory effect of MBL is specific.
MBL attenuates allogeneic T cell proliferation induced by
LPS-stimulated MDCs
As mature DCs are known to be the most potent T cell
activators, we next tested whether MBL affects the
Figure 1 Analyses of the purified MBL protein by SDS-PAGE
and western blotting. (A) The purified MBL under non-reducing
conditions; (B) the purified MBL under reducing conditions;
(C) western blot of the purified MBL under non-reducing conditions;
(D) western blot of the purified MBL under reducing conditions.
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LPS-stimulated MDCs. As demonstrated in Figure 4,
T lymphocytes induced by LPS-stimulated MDCs co-
cultured with MBL (15 μg / m l )s h o w e ds i g n i f i c a n t l y
lower proliferation than the corresponding MDCs with-
o u tM B Lt r e a t m e n t( P <0 . 0 5 ) ;H S A( 1 5μg/ml) had no
effect. In control samples, MDCs incubated in medium
only or primed with LPS were used for the mixed lym-
phocyte reaction. Inclusion of anti-MBL pAb during the
preincubation of the cells with MBL restored allogeneic
T cell proliferation (Figure 4), further indicating the spe-
cific inhibitory effect of MBL.
MBL attenuates the binding of LPS to imMDCs
We next examined whether MBL altered LPS binding to
imMDCs. When the cells were incubated at 4°C with
labeled smooth LPS (Figure 5A), significant LPS binding
was observed on the cell surface (Figure 5A, dotted
line). After the cells were preincubated with MBL
(10 μg/ml), this cell-surface binding of the labeled
smooth LPS was significantly attenuated (Figure 5A,
black solid line). Inclusion of anti-MBL pAb during the
preincubation of the cells with MBL restored the bind-
ing of smooth LPS to the cell surface (Figure 5B), indi-
cating that MBL specifically inhibits the interaction
between smooth LPS and the imMDCs.
We also checked whether MBL itself can bind to the
LPS used in present experiments. The results showed
that MBL bound to rough LPS from E. coli O111: B4
Figure 2 MBL suppresses LPS-induced MDC maturation.
ImMDCs were stimulated with LPS (100 ng/ml) in the presence of
the indicated concentrations of HSA, MBL, or MBL and anti-MBL
pAb for 2 days. Cell maturation was assessed by flow cytometry.
*P < 0.05 as compared to LPS-stimulated group. Similar results were
observed in three independent experiments.
Figure 3 MBL inhibits LPS-induced cytokine production from
imMDCs. ImMDCs were stimulated with LPS (100 ng/ml) in the
presence of the indicated concentrations of HSA, MBL, or MBL and
anti-MBL pAb for 24 h. Supernatants were harvested and subjected
to ELISA for IL-12 p40+p70(A) and TNF-a (B). *P < 0.05 as compared
to LPS-stimulated group. Similar results were observed in three
independent experiments.
Figure 4 MBL attenuates allogeneic T cell proliferation induced
by LPS-primed MDCs. T cells obtained from PBMC (2 × 10
5 cells/
well) were co-cultured with either imMDCs, MBL-preincubated and
LPS-primed MDCs, HSA-preincubated and LPS-primed MDCs, or
LPS-primed MDCs at the indicated DC:T cell ratios. Anti-MBL pAb
was used to demonstrate the specificity of the MBL-induced
response. Proliferation of T cells was determined after 4 days of
culture by
3H-thymidine uptake. Data given as mean ± S.D. of
triplicate samples are representative of four independent
experiments. *P < 0.05 as compared to LPS-stimulated group.
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B4 (Additional file 1, Fig. S1), suggesting that the MBL-
imMDCs interaction rather than an MBL-LPS interac-
tion affects the LPS-induced cellular responses.
Ca
2+-dependent binding of MBL to imMDCs
When imMDCs were incubated with biotinylated MBL
at physiological calcium concentrations (buffer A), there
was definite but slight MBL binding to the cells, as
demonstrated by FCM (Figure 6A). At higher Ca
2+ con-
centrations the binding was markedly increased (Figure
6B,C); also, the binding was markedly reduced in the
absence of Ca
2+ (Figure 6D). These results showed that
MBL interacted with imMDCs in a Ca
2+-dependent
manner.
MBL inhibits NF-B DNA-binding and translocation in
imMDCs
The next question is whether MBL modulates LPS-
induced signaling as a consequence of its interaction with
surface molecules on imMDCs. Therefore, we investi-
gated the effects of MBL on LPS-induced NF-Ba c t i v a -
tion in imMDCs, using two methods: electrophoretic
mobility shift assay (EMSA) and western blotting. For
EMSA, when nuclear extracts from LPS-stimulated
imMDCs were incubated with p40 NF-B probe, NF-B
binding was enhanced within 1 h after LPS-stimulation,
and MBL (15 μg/ml) reduced the DNA binding activity;
DNA binding was restored by including anti-MBL pAb
(Figure 7A). This binding of the complex was specific
because it could be competed away with a 100-fold molar
excess of unlabeled consensus NF-B oligonucleotide
(data not shown). For western blotting, analysis of corre-
sponding nuclear fractions using anti-p65 Ab confirmed
that LPS significantly increased NF-Bt r a n s l o c a t i o n
from the cytoplasm to the nucleus in imMDCs, and treat-
ment with 15 μg/ml MBL strongly inhibited this effect
(Figure 7B). Inclusion of anti-MBL pAb restored NF-B
translocation from the cytoplasm to the nucleus (Figure
7B), further indicating the specific inhibitory effect of
MBL on the interaction between smooth LPS and the
imMDCs.
Discussion
This study demonstrates a new biological function of
MBL in regulating LPS-induced MDCs maturation and
cytokine production. MBL bound to imMDCs at phy-
siological calcium concentrations, but binding was
optimal at supraphysiological concentrations. Further-
more, direct binding of MBL to imMDCs attenuated
the binding of LPS to the cell surface and decreased
LPS-induced NF-B activity, suggesting that it affected
MDC functions by modifying the LPS-induced cellular
responses.
Figure 5 MBL attenuates the binding of smooth LPS to imMDCs. ImMDCs were preincubated with (black solid line) or without (dotted line)
MBL (10 μg/ml) for 30 min (A), or with anti-MBL pAb (30 μg/ml) and MBL (black solid line) for 30 min (B), and further incubated at 4°C for
30 min with Alexa488-labeled smooth LPS (E. coli O111: B4). The binding of LPS on the cell surface was determined by FACScan. The histograms
shown are representatives from three experiments. Shaded curves, the negative control without labeled LPS. (C) Mean fluorescence intensity,
data given as mean ± S.D. from three independent experiments. *P < 0.05 as compared to LPS group.
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initiation of adaptive immunity [12]. They recognize
pathogens through pattern recognition receptors (PRRs)
that are triggered by pathogen-associated molecular pat-
terns, leading to DC maturation. Maturation is a key
process in DC biology and determines whether an
immune response or tolerance will be initiated upon
interaction with a given antigen. It is well accepted that
imDCs induce T cell tolerance by inducing regulatory
T cells [25]. To determine whether MBL affects LPS-
induced MDC maturation, imMDCs were cultivated
with MBL at a range of final concentrations from 0 to
20 μg/ml. The results showed that cells treated with
high MBL concentrations (10-20 μg/ml) expressed sig-
nificantly less CD83, CD86, and MHC II than the corre-
sponding MDCs stimulated with LPS only. In addition,
the proliferation of allogeneic T lymphocytes induced by
LPS-treated MDCs was significantly inhibited when they
were co-cultured with 15 μg/ml MBL, suggesting that
MBL could regulate adaptive immune systems by modu-
lating DC maturation.
Recently Macdonald et al.[ 2 6 ]r e p o r t e dt h a tr h M B L
did not directly influence DC differentiation or matura-
tion. Mature DCs, prepared in the presence of rhMBL
Figure 6 Ca
2+-dependent binding of MBL to imMDCs. (A) Tris-buffered saline with 1.5 mM CaCl2; (B) Tris-buffered saline with 5 mM CaCl2;
(C) Tris-buffered saline with 10 mM CaCl2; (D) Tris-buffered saline with 5 mM EDTA. Each solution of imMDCs was added with the biotinylated
MBL (10 μg/ml) for 10 min incubation before addition of ExtrAvidin-FITC. After incubation for 30 min on ice, binding of MBL to the cells was
analyzed by FACScan, as shown in the representative histograms (A-D). Black lines, biotinylated MBL binding; dotted lines, negative controls (the
cells only). These data are representative of four independent experiments.
Figure 7 MBL decreases LPS-stimulated NF-B binding activity
and translocation in imMDCs. (A) LPS-induced DNA-binding
activity of NF-B is inhibited by MBL. ImMDCs (5 × 10
5 cells/sample)
were stimulated with LPS (100 ng/ml) in the presence of 15 μg/ml
of HSA, anti-MBL pAb and MBL, or MBL for 1 h, then harvested to
prepare nuclear extracts. The nuclear extracts were mixed with
radiolabeled NF-B oligonucleotide probe and analyzed with EMSA.
(B) MBL inhibits NF-B translocation in imMDCs. ImMDCs (5 × 10
5
cells/sample) were stimulated with LPS (100 ng/ml) in the presence
of 15 μg/ml HSA, anti-MBL pAb and MBL, or MBL for 1 h, then the
cells were harvested to prepare nuclear extracts. The proteins in the
nuclei-free supernatants were separated by 10% SDS-PAGE, followed
by transfer to a nitrocellulose membrane. After blocking, the
membrane was incubated with the NF-B-specific mouse anti-
human mAb p65, followed by HRP-conjugated secondary antibody.
ECL was used to visualize the protein bands. As an internal control,
actin was used.
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lear cells, markedly promoted the production of IL-1,
IL-6 and TNF-a in vitro. This influence required the
presence of rhMBL during DC maturation and was criti-
cally dependent on the presence of monocytes. How-
ever, the data presented in this study demonstrate that
MBL suppresses DC maturation and cytokine secretion
in the presence of LPS in vitro, suggesting that MBL
may act differently under different (physiological or
pathological) conditions and shows much versatility in
regulating cellular immunity in addition to its estab-
lished role as an opsonin.
It has been recognized that the nature of the innate
immune response significantly influences the nature of
the subsequent adaptive immune response. Both soluble
and membrane-bound PRRs of the innate immune sys-
tem assess the level of danger of a particular intrusion
and initiate a program of protection for the host [27].
Phagocytic cells (e.g., monocytes, macrophages and
DCs) mediate some of these changes, when activated by
pathogens, which often initiate the synthesis of proin-
flammatory cytokines [28]. T h ec y t o k i n ee n v i r o n m e n t
then influences the subsequent specific immune
responses. This study provides strong evidence that
MBL at higher concentrations (10-20 μg/ml), but not at
lower concentrations (1 μg/ml), significantly inhibits
LPS-induced TNF-a and IL-12 p40+p70 production,
indicating that could affect the adaptive immune
response by modulating the cytokine network.
It is known that mouse MBL-A interacts with the
rough but not the smooth LPS [29]. Estabrook et al.
[30] and Sprong et al.[ 3 1 ]a l s op r o v e dt h a th u m a n
MBL did not interact with LPS. In the present study,
smooth LPS was used to avoid interference from any
LPS-MBL interaction. We also demonstrated that MBL
itself did not bind to the smooth LPS used in this study.
This evidence strongly supports the view that the MBL-
imMDC interaction rather than the MBL-LPS interac-
tion affects LPS-induced cellular responses.
The functional MBL receptor expressed by many cell
types is still controversial. As a major soluble PRR in
the innate immune system, MBL has long been known
to recognize pathogens or autologous apoptotic cells via
its CRD and to interact with autologous cells via its
CLR. It was believed that the CRD does not interact
with normal autologous cells, but recently Downing
et al. [32] reported calcium-dependent MBL binding to
autogeneic B lymphocytes, monocytes and imMDCs via
its C-type lectin-binding site, suggesting a new role of
M B Li nt h ei m m u n es y s t e m .I nt h i ss t u d y ,t h e r ew a s
clear evidence to demonstrate that MBL binds imMDCs
at physiological calcium concentrations, though the
binding was optimal at supraphysiological concentra-
tions. SP-A directly interacts with TLR4 and MD-2 and
regulates inflammatory cellular responses [33], and MBL
and lung collectins interact with TLR4 and MD-2 by
different mechanisms [34]. As LPS/TLR- signaling path-
ways are crucial for controlling the early inflammatory
response and TLR4 is critical for LPS recognition and
signaling [35], we presumed that TLR4 might be directly
involved in MBL binding to the cell surface. It is also
well known that LPS recognition is a complex process
involving cooperation of several molecules such as LBP,
CD14 and MD2, which enhance TLR4 signaling. Rat
MBL might interact with CD14 [29]. Therefore, other
cell surface molecules might play a role through binding
to MBL. However, the molecular mechanisms by which
MBL interacts with cells need to be investigated further.
LPS-activated cells sometimes induce microcirculatory
dysfunction as well as inflammatory changes, which
cause injury to various tissues, circulatory failure, and
occasionally death [36-38]. To prevent excessive and
prolonged responses by host innate immune cells to
LPS, the host may acquire a down-regulating system,
LPS tolerance, which ensures safe responses to LPS and/
or unresponsiveness to a second stimulation [39]. The
fact that MBL at higher concentrations inhibits LPS-
induced DC maturation and proinflammatory cytokine
secretion suggests that it could provide such down-regu-
lation in an inflammatory situation. In addition, the
MBL preparation used in this study was determined
without endotoxin by the Limulus amebocyte lysate
assay, ruling out LPS tolerance induced by endotoxin
contamination in the MBL preparations.
The serum concentration of MBL normally ranges
from 0.01 to 10 μg/ml [40-42], but as an acute-phase
protein, this can increase from 1.5- to 3-fold in
patients during an acute phase response [43]. The
serum levels of MBL in patients with rheumatic heart
disease increased significantly up to 14 μg/ml [44].
MBL is also present in such extravascular milieux as
synovial fluid, amniotic fluid, lung and vaginal lavages
[45-49], and behaves as an acute-phase reactant in
individuals with ‘sufficient’ (wild-type) MBL genotypes
[50]. Therefore, we presume that MBL binding to
autologous cells is most likely to take place at inflam-
matory loci, where local elevation of the extravascular
MBL concentration and a concomitant influx of
immune system cells are to be expected. The data pre-
sented in this paper showed that LPS-induced MDC
functions were significantly modulated by MBL at
higher concentrations (10-20 μg / m l )b u tn o ta tl o w e r
concentrations (1 μg/ml). Therefore, by analogy, we
presume that further investigations could provide evi-
dence that, in the acute phase, high-concentration
MBL is secreted to affect cytokine-mediated immune
regulation in the serum as well as locally in some
extravascular tissues.
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anti-inflammatory effects in pathological states. As a
common exogenous pathogenic factor, LPS is not only a
major mediator in the systemic inflammatory response
and sepsis, but also a strong activator of monocytes,
macrophages and DCs. During inflammatory shock, LPS
stimulates monocytes to produce excessive inflammatory
mediators and their cascade reactions, leading to multi-
ple organ failure. Numerous studies have confirmed that
the imbalanced cytokines mediating the interaction of
natural and acquired immunity contribute to human
sepsis and immune dysfunctions. Overproduction of
proinflammatory cytokines (e.g. TNF-a,I L - 1 2 ,I F N - g
and IL-18) results in sustained sepsis, shock, and even
death [51,52]. In this study, higher concentrations of
MBL inhibited LPS-induced DC maturation and the
secretion of such proinflammatory cytokines as TNF-a
and IL-12, indicating that MBL might be implicated in
the anti-inflammatory effect and immunoregulation,
reducing the incidence of shock and prevent endotoxe-
mia-induced death. This study paves the way for a novel
treatment of inflammatory shock by modulating exces-
sive activated DCs with MBL.
Conclusions
In summary, we demonstrated in this study that MBL
could attenuate MDCs maturation and cytokine produc-
tion induced by LPS. MBL also bound directly to imMDCs
and attenuated the binding of LPS to the cell surfaces,
resulting in decreased LPS-induced nuclear NF-Ba c t i v i t y
in these cells. All these data suggest that MBL could affect
the functions of DCs by modifying LPS-induced cellular
responses. This study supports an important role for MBL




MBL was isolated from human plasma according to Tan
et al. [53], modified as described [54]. Briefly, a pool of
freshly frozen human plasma (2.5 liters) (provided by
Guangzhou General Hospital of Guangzhou Military
Area Command of Chinese PLA, China) was thawed
from -80°C and, after extraction and elimination of
most of the unrelated proteins, the residual fraction was
solubilized and MBL was purified by a process involving
three chromatographic steps. The first step was affinity
chromatography on a mannan-agarose (Sigma, Poole,
UK) column, which selected for functionally active, car-
bohydrate-binding MBL with about 2000-fold purifica-
tion. The subsequent steps were anion-exchange
chromatography and gel filtration on a Mono-Q HR 5/5
column (Pharmacia Biotech Europe, Orsay, France) and
a Superose 6 HR 10/30 column (Pharmacia Biotech,
Orsay, France), respectively. The purified MBL was eval-
uated by SDS-PAGE and western blotting.
The MBL preparation was determined without endo-
toxin contamination by the Limulus amebocyte lysate
assay. Biotinylated MBL was prepared by coupling N-
hydroxysuccinimidobiotin to the purified MBL as
described [55].
Preparation of human DCs
DCs were prepared from peripheral blood monocytes of
healthy individuals. Briefly, peripheral blood mononuc-
lear cells (PBMCs) were isolated by standard density gra-
dient centrifugation and further separated on multistep
Percoll gradients (Pharmacia, Uppsala, Sweden). The
cells were suspended in IMDM (Gibco BRL, Gaithers-
burg, MD, USA) and allowed to adhere to 6-well tissue
culture plates (Corning-Costar, MA, USA). After incuba-
tion for 40 min at 37°C, non-adherent lymphocytes were
removed. Adherent monocytes were harvested and
washed twice, then cultivated for 5 days in IMDM con-
taining rHuGM-CSF (115 ng/ml; Peprotech, Inc., Rocky
Hill, N.J.) and rHuIL-4 (50 ng/ml; Peprotech, Inc.) and
supplemented with 10% (v/v) heat-inactivated fetal calf
serum (FCS, Gibco BRL, Grand Island, CA), penicillin
(100 U/ml) and streptomycin (100 μg/ml). The cells were
kept in culture at a density of 10
6 cells/ml in 12-well
plates (Corning-Costar, MA, USA) at 37°C in a 5% (v/v)
CO2 atmosphere. On day 3, additional rHuGM-CSF (115
n g / m l )a n dr H u I L - 4( 5 0n g / m l )w e r ea d d e dt ot h ec u l -
tures. On day 5, imMDCs were harvested by centrifuga-
tion at 450 × g for 5 min and washed with IMDM before
the experiments.
To study the effect of MBL on maturation and cyto-
kine production, the harvested imMDCs (1 × 10
6 cells/
ml) were seeded in 12-well plates in complete IMDM,
and maintained at 37°C in a 5% (v/v) CO2 environment
for 2 h after MBL was added to a range of final concen-
trations (0-20 μg/ml). rHuGM-CSF (115 ng/ml) and
rHuIL-4 (50 ng/ml), and smooth LPS (100 ng/ml; from
E. coli O111: B4, Campbell, CA), were added to the
complete medium. Samples were kept at 37°C under a
humidified 5% CO2 environment for 2 days, and then
analyzed. In control groups, human serum albumin
(HSA, 20 μg/ml) was used. To demonstrate the specifi-
city of the responses to MBL, anti-MBL pAb (R&D sys-
tems, MN, USA) was used.
Flow cytometric determination of MDC phenotypes
To determine phenotypes, MDCs were washed and then
incubated in PBS containing 2% FCS and 0.01% NaN3,
with the following monoclonal antibodies (mAbs):
FITC-conjugated anti-human HLA-DR and FITC-conju-
gated anti-human CD14 (Becton Dickinson, San Jose,
USA), PE-conjugated anti-human CD1a, PE-conjugated
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PE-conjugated anti-human CD83, FITC-conjugated anti-
mouse IgG, and control mouse IgG (eBioscience, San
Diego, USA). In control samples, the mAbs were substi-
tuted with matched isotype control mouse Ig (Becton
Dickinson, San Jose, USA). Cells were analyzed in a
FACScan equipped with Cell Quest software (Becton
Dickinson, Mountain View, USA).
Cytokine measurements
The supernatants of the various samples were collected
and stored at -80°C pending analysis. For negative con-
trols, the cells were cultured in complete medium only.
Production of IL-12 p40+p70 and TNF-a were deter-
mined using ELISA kits (Bender MedSystems, San
Diego, USA), as suggested by the manufacturers.
Mixed lymphocyte reaction (MLR)
CD3
+ T cells were isolated from PBMCs as described
[56]. Isolated T cells were transferred to 96-well flat-
bottom microplates (Corning-Costar, MA, USA) at a
density of 2 × 10
5 cells/well. These T cells were co-
cultured with LPS-induced DCs preincubated with 15
μg/ml MBL in the indicated DC:T cell ratios, without
additional exogenous cytokine. To demonstrate the
specificity of responses toM B L ,a n t i - M B Lp A bw a s
used. Proliferation of T cells was determined by
3H-
thymidine (Perkin-Elmer, MA, USA) incorporation.
Net counts per minute (cpm) were measured in tripli-
cate cultures.
Effect of MBL on the binding of LPS to imMDCs
ImMDCs were collected, and 10
6 cells/tube were prein-
cubated in the absence or presence of 10 μg/ml MBL at
37°C for 30 min. The cells were then further incubated
with 100 ng/ml Alexa488-labeled smooth LPS (E. coli
O111: B4, the molecular mass is ~10,000 Da, Molecular
Probes, MN, USA) at 4°C for 30 min. After washing, the
cells were analyzed by FACScan. To demonstrate the
specificity of the response to MBL, anti-MBL pAb was
added to MBL preparations for 10 min before incubat-
ing with the cells.
Binding of MBL to imMDCs
The ligand binding assay was performed as described
[57]. Washed imMDCs (2 × 10
5) were resuspended in
Tris-buffered saline (pH7.4) containing 5 mM CaCl2,1 %
bovine serum albumin (buffer A). Three kinds of Tris-
buffered saline containing different calcium concentra-
tions were alternatively used for binding assays. In the
Ca
2+-free control, 5 mM EDTA was substituted for
CaCl2. Each cell suspension (0.2 ml) was first incubated
for 30 min on ice with either biotinylated MBL or unla-
belled MBL. The cells were incubated further for 30
m i no ni c ew i t hE x t r A v i d i n - F I T C( S i g m a ,M a d r i d ,
Spain) at a final dilution of 1 in 100. After washing, the
cells were analyzed by FACSCalibur.
The possibility that MBL itself binds to the LPS used
in the experiments was also examined using microtiter
wells. Smooth LPS (E. coli O111: B4), rough LPS
[E. coli O111: B4 mutant (J5)] or mannan (10 μg/ml,
50 μl/well; Sigma, St. Louis, USA) was coated on to
the wells, which were incubated with 10 mM Hepes
buffer (pH 7.4) containing 0.15 M NaCl, 5 mM CaCl2,
and 5% (w/v) BSA (buffer B) to block nonspecific bind-
ing. The indicated concentrations of MBL in buffer B
w e r ea d d e da n di n c u b a t e da t3 7 ° Cf o r1h .A f t e rw a s h -
ing, the wells were incubated with anti-human MBL
mAb (1:5000). Binding was detected with HRP-labeled
goat anti-mouse IgG, and the absorbance at 450 nm
was measured.
Analyses of NF-kB by EMSA and western blotting
ImMDCs (5 × 10
5 cells/sample) were stimulated with
LPS (100 ng/ml) in the presence of 15 μg/ml MBL,
HAS, or MBL and anti-MBL pAb for 1 h. The DCs
were harvested and nuclear extracts were prepared
using the NucBuster protein extraction kit (Novagen,
Darmstadt, Germany). Oligonucleotide probes were
radiolabeled with [g-
32P] ATP by T4 polynucleotide
kinase (Takara, Tokyo, Japan). For the binding reaction,
5 μg of nuclear extracts were incubated in 30 μlt o t a l
reaction buffer containing 10 mM Hepes (pH 7.9),
12.5% glycerol, 70 mM NaCl, 1 mM DTT, 1 mM
EDTA, and 2 μg poly(dI:dC). The
32P-labeled oligonu-
cleotide was added to the reaction mixture and incu-
bated for 20 min at room temperature. Samples were
electrophoresed on 6% acrylamide gels (made with 50
mM Tris buffer containing 380 mM glycine and 2 mM
EDTA), followed by autoradiography.
For western blotting, the extracts were separated by
10% SDS-PAGE, followed by transfer to a nitrocellu-
lose membrane (BioRad, CA, USA). After blocking
with 5% fat-free milk protein in triethanolamine-
buffered saline (TBS), pH 7.5, the membrane was incu-
bated with the NF-B-specific mouse anti-human mAb
p65 (Santa Cruz Biotechnology, CA, USA). After wash-
ing, HRP-conjugated secondary antibody was added to
the membrane in TBS containing 0.1% Tween 20. As
an internal control, actin was used. An enhanced che-
miluminescence detection system (ECL, Amersham
Biosciences, Sweden) was used to visualize the protein
bands.
Statistical analysis
The mean and SD were calculated by Excel software
(Microsoft). Student’s t-test was used for statistical ana-
lysis, and P < 0.05 was considered significant.
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Additional file 1: Fig. S1: MBL does not bind to smooth LPS.
Microtiter wells were coated with smooth LPS, rough LPS or mannan (10
μg/ml, 50 μl/well), and incubated with MBL at 37°C for 1 h. The binding
of MBL was detected using anti-MBL mAb and HRP-labeled goat anti-
mouse IgG as described under “Methods”. The data shown are means ±
S.E. of three experiments.
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